Bioburden Testing Market

Executive Summary

Bioburden Testing Market was valued at US $716.99 million in 2021 and is projected to grow at 12.19% CAGR over the forecast period to reach US $1,429.45 million by 2027. Bioburden Testing Market represented US $147.31 million opportunity over 2019-2021 and estimated to create US $712.46 million opportunity in 2027 over 2021.

Bioburden Testing from Consainsights analyses the Bioburden Testing Market in the Life Sciences industry over the forecast period to 2027.

Bioburden Testing research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Bioburden Testing segmentation includes Product, Test Type, Application, End User, Region and Geography.

Based on the Product, the Bioburden Testing analysis covers Consumables, Instruments.

In Product segment, Consumables segment has highest cagr growth of 10.76%.

Based on the Test Type, the Bioburden Testing analysis covers Aerobic Count Testing, Anaerobic Count Testing, Fungi/Mold Count Testing, Spore Count Testing.

In Test Type segment, Aerobic Count Testing segment has highest cagr growth of 10.76%.

Based on the Application, the Bioburden Testing analysis covers Raw Material Testing, Medical Device Testing, In-Process Material Testing, Sterilization Validation Testing, Equipment Cleaning Validation.

In Application segment, Raw Material Testing segment has highest cagr growth of 10.76%.

Based on the End User, the Bioburden Testing analysis covers Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Contract Manufacturing Organizations, Manufacturers of Food & Beverage and Agricultural Products, Microbial Testing Laboratories.

In End User segment, Pharmaceutical & Biotechnology Companies segment has highest cagr growth of 10.76%.

Based on the Region, the Bioburden Testing analysis covers North America, Europe, Asia, Rest of the World.

In Region segment, North America segment has highest cagr growth of 10.76%.

Based on the region, the Bioburden Testing analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Charles River, Merck KGaA, SGS SA, Wuxi Apptec, BD, North American Science Associates Inc. (NAMSA), Nelson Laboratories, LLC, Thermo Fisher Scientific, Biomérieux SA, Pacific Biolabs and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Consumables segment has the highest revenue of US $473.03 million and is expected to grow at CAGR of 10.76% by 2027 Consumables segment has highest cagr growth of 10.76%.

Consumables

Consumables segment was valued at US $375.84 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $943.07 million by 2027. Consumables segment represented US $97.19 million opportunity over 2019-2021 and estimated to create US $470.04 million opportunity in 2027 over 2021.

Instruments

Instruments segment was valued at US $193.84 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $486.39 million by 2027. Instruments segment represented US $50.13 million opportunity over 2019-2021 and estimated to create US $242.42 million opportunity in 2027 over 2021.

Test Type

Introduction

In 2021, Aerobic Count Testing segment has the highest revenue of US $312.39 million and is expected to grow at CAGR of 10.76% by 2027 Aerobic Count Testing segment has highest cagr growth of 10.76%.

Aerobic Count Testing

Aerobic Count Testing segment was valued at US $248.21 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $622.81 million by 2027. Aerobic Count Testing segment represented US $64.19 million opportunity over 2019-2021 and estimated to create US $310.42 million opportunity in 2027 over 2021.

Anaerobic Count Testing

Anaerobic Count Testing segment was valued at US $143.37 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $359.74 million by 2027. Anaerobic Count Testing segment represented US $37.07 million opportunity over 2019-2021 and estimated to create US $179.30 million opportunity in 2027 over 2021.

Fungi/Mold Count Testing

Fungi/Mold Count Testing segment was valued at US $124.18 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $311.60 million by 2027. Fungi/Mold Count Testing segment represented US $32.11 million opportunity over 2019-2021 and estimated to create US $155.31 million opportunity in 2027 over 2021.

Spore Count Testing

Spore Count Testing segment was valued at US $53.92 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $135.30 million by 2027. Spore Count Testing segment represented US $13.94 million opportunity over 2019-2021 and estimated to create US $67.44 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, Raw Material Testing segment has the highest revenue of US $276.93 million and is expected to grow at CAGR of 10.76% by 2027 Raw Material Testing segment has highest cagr growth of 10.76%.

Raw Material Testing

Raw Material Testing segment was valued at US $220.03 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $552.10 million by 2027. Raw Material Testing segment represented US $56.90 million opportunity over 2019-2021 and estimated to create US $275.18 million opportunity in 2027 over 2021.

Medical Device Testing

Medical Device Testing segment was valued at US $145.86 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $365.99 million by 2027. Medical Device Testing segment represented US $37.72 million opportunity over 2019-2021 and estimated to create US $182.42 million opportunity in 2027 over 2021.

In-Process Material Testing

In-Process Material Testing segment was valued at US $109.24 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $274.12 million by 2027. In-Process Material Testing segment represented US $28.25 million opportunity over 2019-2021 and estimated to create US $136.63 million opportunity in 2027 over 2021.

Sterilization Validation Testing

Sterilization Validation Testing segment was valued at US $52.12 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $130.79 million by 2027. Sterilization Validation Testing segment represented US $13.48 million opportunity over 2019-2021 and estimated to create US $65.19 million opportunity in 2027 over 2021.

Equipment Cleaning Validation

Equipment Cleaning Validation segment was valued at US $42.42 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $106.45 million by 2027. Equipment Cleaning Validation segment represented US $10.97 million opportunity over 2019-2021 and estimated to create US $53.05 million opportunity in 2027 over 2021.

End User

Introduction

In 2021, Pharmaceutical & Biotechnology Companies segment has the highest revenue of US $324.39 million and is expected to grow at CAGR of 10.76% by 2027 Pharmaceutical & Biotechnology Companies segment has highest cagr growth of 10.76%.

Pharmaceutical & Biotechnology Companies

Pharmaceutical & Biotechnology Companies segment was valued at US $257.74 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $646.73 million by 2027. Pharmaceutical & Biotechnology Companies segment represented US $66.65 million opportunity over 2019-2021 and estimated to create US $322.34 million opportunity in 2027 over 2021.

Medical Device Manufacturers

Medical Device Manufacturers segment was valued at US $167.62 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $420.61 million by 2027. Medical Device Manufacturers segment represented US $43.35 million opportunity over 2019-2021 and estimated to create US $209.64 million opportunity in 2027 over 2021.

Contract Manufacturing Organizations

Contract Manufacturing Organizations segment was valued at US $89.42 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $224.39 million by 2027. Contract Manufacturing Organizations segment represented US $23.12 million opportunity over 2019-2021 and estimated to create US $111.84 million opportunity in 2027 over 2021.

Manufacturers of Food & Beverage and Agricultural Products

Manufacturers of Food & Beverage and Agricultural Products segment was valued at US $45.71 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $114.69 million by 2027. Manufacturers of Food & Beverage and Agricultural Products segment represented US $11.82 million opportunity over 2019-2021 and estimated to create US $57.16 million opportunity in 2027 over 2021.

Microbial Testing Laboratories

Microbial Testing Laboratories segment was valued at US $9.18 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $23.04 million by 2027. Microbial Testing Laboratories segment represented US $2.37 million opportunity over 2019-2021 and estimated to create US $11.48 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $256.72 million and is expected to grow at CAGR of 10.76% by 2027 North America segment has highest cagr growth of 10.76%.

North America

North America segment was valued at US $203.97 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $511.82 million by 2027. North America segment represented US $52.75 million opportunity over 2019-2021 and estimated to create US $255.10 million opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $188.37 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $472.67 million by 2027. Europe segment represented US $48.71 million opportunity over 2019-2021 and estimated to create US $235.59 million opportunity in 2027 over 2021.

Asia

Asia segment was valued at US $110.85 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $278.16 million by 2027. Asia segment represented US $28.67 million opportunity over 2019-2021 and estimated to create US $138.64 million opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $66.48 million in 2019 and is projected to grow at 10.76% CAGR over the forecast period to reach US $166.81 million by 2027. Rest of the World segment represented US $17.19 million opportunity over 2019-2021 and estimated to create US $83.14 million opportunity in 2027 over 2021.